Iomeron (Iomeprol)

Iomeprol contains iodine atoms with a high atomic number that absorb X‑ray photons. After injection, it distributes within the vascular and extracellular spaces, raising the X‑ray attenuation of blood and tissues. This creates a contrast difference between vessels and surrounding structures, allowing clearer radiographic images.

The dose of Iomeron is determined by the prescribing physician based on the specific imaging study, patient weight, renal function, and clinical protocol. Dosage calculations are individualized and should follow the recommendations of the imaging department and relevant regulatory guidelines.

The safety of Iomeron in pregnancy or while breastfeeding has not been definitively established. Use is generally avoided unless the diagnostic benefit outweighs potential risk. Clinicians should assess each case carefully and consider alternative imaging methods when possible.

To order Iomeron, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team will then respond with pricing, availability, shipping details (including any cold‑chain requirements) and required import documentation.

Iomeron is a non‑ionic, low‑osmolality iodinated contrast medium, offering a favorable safety profile compared with older high‑osmolality agents. Compared with other non‑ionic agents, it provides similar image quality while potentially reducing the incidence of adverse reactions, especially in patients with mild renal impairment.

Iomeron should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Protect the solution from direct sunlight, moisture and extreme temperature fluctuations. Do not freeze or shake the vial before use.

Iomeron is administered as a sterile solution for injection via the intra‑arterial or intravenous route. The injection is performed by qualified healthcare professionals under imaging guidance, using the dosage and injection rate recommended for the specific diagnostic procedure.

The most serious risks include severe allergic reactions such as anaphylaxis, acute renal impairment especially in patients with pre‑existing kidney disease, and cardiovascular events like hypotension or arrhythmias. Prompt recognition and management of these reactions are essential.

Iomeron should be avoided in patients with a known hypersensitivity to iodinated contrast media, severe uncontrolled hyperthyroidism, or those with critically impaired renal function where alternative imaging methods are feasible. Clinicians must evaluate individual risk factors before administration.